医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GreenComm Commercializes the Motion Recognition Technology for ‘a Wearable Device Distinguishing Motions’

2015年01月08日 AM07:25
このエントリーをはてなブックマークに追加


 

SAN JOSE, Calif.

A wearable device, which helps healthcare by recognizing the detailed actions of the user, e.g. jump roping and playing soccer as well as walking and running, has been developed in Korea.

GreenComm (CEO Shin Ki-chul) announced on December 30 that it developed the ‘iBody 24 Planner,’ a healthcare wearable device using the motion recognition technology.

Worn like a wrist watch, this device uses the tri-axial accelerometer, barometer and software to distinguish the actions of the user. For instance, device is able to determine type of exercise user did, e.g. tennis, golf and table tennis as well as walking and running, and how many calories he/she burned up.

It is based on recognition of movement patterns through sensors. As for golf, the sensor data varies when the user swings. The data pattern for each movement is used to tell what exercise the user is doing. GreenComm says that the device uses the speed and duration of movement and the intensity of the exercise along with the movement pattern to calculate calories consumed.

“As it automatically recognizes all activities of the user, the device overcomes the weaknesses of other devices that must have manual selections for different exercises,” said Shin Ki-chul, CEO of GreenComm. “As it can be used indoors, efficient healthcare is also possible.”

GreenComm said that the company co-developed technology led by Dr. Lee Taek-jin of KIST and his team. The company added that it combined this technology with the middleware it developed on its own to turn it into a wearable device.

GreenComm is planning to commercialize it in March 2015. It will introduce the technology and product at the Consumer Electronics Show (CES) held in Las Vegas, US in January.

CONTACT

Greencomm Co.
Shin Ki-chul, 408-519-5749
CEO

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
  • Genexine Announces Dosing of First Patient in Phase 2 clinical trial with Triple Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
  • クリアがCOVID-19声明に関する政府の訴訟に対して修正答弁書を提出、クリア製品の追加防御層としての使用を支持するデータをさらに提供
  • Integral Group Australia Rebranding as Introba to Align with Global Brands
  • 针对政府就新冠病毒声明提起的诉讼,Xlear提交修正后的答复;通过更多数据继续支持Xlear作为额外防护层使用